83 related articles for article (PubMed ID: 8203754)
1. Synthesis of a N'-alkylamine anticoagulant active low-molecular-mass heparin for radioactive and fluorescent labeling.
Malsch R; Guerrini M; Torri G; Löhr G; Casu B; Harenberg J
Anal Biochem; 1994 Mar; 217(2):255-64. PubMed ID: 8203754
[TBL] [Abstract][Full Text] [Related]
2. Semisynthesis and analysis of lipophilically modified unfractionated and low molecular mass heparins.
Malsch R; Harenberg J; Guerrini M; Torri G; Casu B; Heene DL
Semin Thromb Hemost; 1994; 20(2):182-92. PubMed ID: 7997890
[TBL] [Abstract][Full Text] [Related]
3. N' alkylamine low molecular mass heparins (LMM-heparin-tyramine and LMM-heparin-tyramine-fitc) exhibit long lasting anticoagulant effects.
Malsch R; Piazolo L; Harenberg J; Heene DL
Thromb Res; 1995 Nov; 80(3):235-46. PubMed ID: 8578550
[TBL] [Abstract][Full Text] [Related]
4. Competitive binding of low molecular mass heparin-tyramine fluorescein-5-isothiocyanate and unlabeled glycosaminoglycans to leukocytes.
Harenberg J; Malsch R; Piazolo L; Heene DL
Semin Thromb Hemost; 1994; 20(3):236-44. PubMed ID: 7824957
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological effects of N-alkylamine-labeled low-molecular-mass dermatan sulfate.
Malsch R; Guerrini M; Berti C; Naggi A; Torri G; Casu B; Harenberg J
Semin Thromb Hemost; 1997; 23(2):99-107. PubMed ID: 9200333
[TBL] [Abstract][Full Text] [Related]
6. Low-molecular-weight heparin and dermatan sulfate end group-labeled with tyramine and fluorescein. Biochemical and biological characterization of the fluorescent-labeled heparin derivative.
Harenberg J; Casu B; Guerrini M; Malsch R; Naggi A; Piazolo L; Torri G
Semin Thromb Hemost; 2002 Aug; 28(4):343-54. PubMed ID: 12244481
[TBL] [Abstract][Full Text] [Related]
7. Binding of fluorescent-labeled low molecular mass heparin to latex microspheres and to rat and human leukocytes.
Piazolo L; Harenberg J; Malsch R; Heene DL
Semin Thromb Hemost; 1994; 20(3):227-35. PubMed ID: 7824956
[TBL] [Abstract][Full Text] [Related]
8. Measurement of fluorescent-labeled LMM-heparin in biological fluids using protamine-linked microbeads.
Malsch R; Melui D; Piazolo L; Harenberg J; Heene DL
Semin Thromb Hemost; 1997; 23(1):23-30. PubMed ID: 9156407
[TBL] [Abstract][Full Text] [Related]
9. Preferential binding of heparin to granulocytes of various species.
Harenberg J; Malsch R; Piazolo L; Huhle G; Heene DL
Am J Vet Res; 1996 Jul; 57(7):1016-20. PubMed ID: 8807013
[TBL] [Abstract][Full Text] [Related]
10. High-performance size exclusion chromatography and polyacrylamide gel electrophoresis for characterization of unfractionated and low molecular mass glycosaminoglycans.
Malsch R; Harenberg J
Semin Thromb Hemost; 1994; 20(2):135-43. PubMed ID: 7997884
[TBL] [Abstract][Full Text] [Related]
11. Analysis of heparin binding to human leukocytes using a fluorescein-5-isothiocyanate labeled heparin fragment.
Harenberg J; Malsch R; Piazolo L; Huhle G; Heene DL
Cytometry; 1996 Jan; 23(1):59-66. PubMed ID: 14650442
[TBL] [Abstract][Full Text] [Related]
12. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
Brieger D; Dawes J
Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
[TBL] [Abstract][Full Text] [Related]
13. Entry and distribution of fluorescent antiproliferative heparin derivatives into rat vascular smooth muscle cells: comparison between heparin-sensitive and heparin-resistant cultures.
Bârzu T; Pascal M; Maman M; Roque C; Lafont F; Rousselet A
J Cell Physiol; 1996 Apr; 167(1):8-21. PubMed ID: 8698843
[TBL] [Abstract][Full Text] [Related]
14. Low-molecular weight molluscan glycosaminoglycan from bivalve Katelysia opima (Gmelin).
Vijayabaskar P; Balasubramanian T; Somasundaram ST
Methods Find Exp Clin Pharmacol; 2008 Apr; 30(3):175-80. PubMed ID: 18597000
[TBL] [Abstract][Full Text] [Related]
15. 5'-(p-fluorosulfonylbenzoyl)-2'(or 3')-(methylanthraniloyl)adenosine, fluorescent affinity labels for adenine nucleotide binding sites: interaction with the kinase active site of the receptor for epidermal growth factor.
Scoggins RM; Summerfield AE; Stein RA; Guyer CA; Staros JV
Biochemistry; 1996 Jul; 35(28):9197-203. PubMed ID: 8703925
[TBL] [Abstract][Full Text] [Related]
16. Liver sinusoidal endothelial cells are the principal site for elimination of unfractionated heparin from the circulation.
Oie CI; Olsen R; Smedsrød B; Hansen JB
Am J Physiol Gastrointest Liver Physiol; 2008 Feb; 294(2):G520-8. PubMed ID: 18063704
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies against heparin and heparinoids.
Huhle G; Harenberg J; Malsch R; Heene DL
Semin Thromb Hemost; 1997; 23(1):17-22. PubMed ID: 9156406
[TBL] [Abstract][Full Text] [Related]
18. Fluorescent isotope-coded affinity tag 2: peptide labeling and affinity capture.
Rivera-Monroy Z; Bonn GK; Guttman A
Electrophoresis; 2009 Apr; 30(7):1111-8. PubMed ID: 19288590
[TBL] [Abstract][Full Text] [Related]
19. [Anticoagulant activity of low-molecular-weight heparins obtained using a hydrolase complex].
Drozd NN; Tolstenkov AS; Bannikova GE; Miftakhova NT; Lapikova ES; Makarov VA; Varlamov VP
Eksp Klin Farmakol; 2007; 70(6):19-24. PubMed ID: 18318190
[TBL] [Abstract][Full Text] [Related]
20. [Anticoagulant activity of low-molecular-weight sulfated derivatives of galactomannan from Cyamopsis tetragonoloba (L.) seeds].
Mestechkina NM; Shcherbukhin VD; Bannikova GE; Varlamov VP; Drozd NN; Tolstenkov AS; Makarov VA; Tikhonov VE
Prikl Biokhim Mikrobiol; 2008; 44(1):111-6. PubMed ID: 18491607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
